9 citations
,
January 2018 in “Acta Clinica Croatica” This review suggests that bendamustine, alone or in combination, shows effectiveness in treating indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia, with recent studies highlighting its benefits especially in combination therapies, while balancing efficacy with a favorable toxicity profile.
24 citations
,
July 2013 in “Oncologist” This study suggests that the combination of bendamustine and rituximab is at least as effective and possibly offers a better therapeutic index than other standard regimens as first-line treatment for certain lymphoma patients.
September 2012 in “International Current Pharmaceutical Journal” In this study, CHOP chemotherapy for intermediate grade Non-Hodgkin's Lymphoma showed predictable toxicities but was generally well tolerated without treatment interruption among most patients.
3 citations
,
January 2019 in “Skin appendage disorders” This case report describes a patient with primary cutaneous follicle center lymphoma who developed an alopecic atrophic patch potentially due to pressure, following rituximab treatment.
7 citations
,
September 2006 in “Clinical lymphoma & myeloma” This review discusses various treatment challenges and toxicities in patients with relapsed follicular lymphoma and suggests that novel therapies could improve outcomes by reducing exposure to harmful chemotherapy cycles.